October 12, 2023 07:25 AM EDT
Financing
Deals

As­tria nabs pre­clin­i­cal OX40 atopic der­mati­tis drug for $15M up­front, prices $64M of­fer­ing

Katherine Lewin

News Reporter

As­tria Ther­a­peu­tics re­vealed it had li­censed Ich­nos Sci­ences’ lead can­di­date for atopic der­mati­tis for an up­front fee of $15 mil­lion be­fore …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times